Aganirsen

Indicaton

Corneal Neovascularisation in Graft Patients (CNV-CG)

Therapeutic indications

Ophthalmology

Table

Partnering status

n/a

You may also be interested in

TOP-N53, TOP-V122, TOP-M119 and TOP-N44

TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.

Phase I started

TOP-N53, TOP-N44, TOP-M119, TOP-V122, TOP-T5

Clinical development for diabetic foot ulcer and digital ulcer. Preclinical development burn wounds, normal tension glaucoma, hair growth and chemotherapy induced hair loss, prevention of colorectal cancer, Elimination of cancer stem cells and skin aging.

Phase I started

TOTIPHARMACEUTICAL

Polypharmacology for all therapeutic aeras using nano-drug delivery systems